

Synthesis, characterization and antimicrobial activity of Mn(II), Fe(III), Co(III), Ni(II), Cu(II) and Zn(II) complexes of a new (O,N) type donor Schiff base ligand derived from Homoveratrylamine and β -Resorcinaldehyde

C.E. Satheesh,^a H. R. Rajegowda,^b Somashekar M. N.^c, GollaRamesh,^a K.Lingaraju,^d
P. RaghavendraKumar,^{a*}

{sathesh.in@gmail.com^a, somu.smn@gmail.com^b, raghukp1@gmail.com^{*}}

^aDepartment of Chemistry, University College of Science, Tumkur University, Tumakuru – 572103, Karnataka, India

^bDepartment of Chemistry, Acharya Institute of Graduate Studies, Soladevanahalli – 560107, Bengaluru, Karnataka, India

^cDepartment of Chemistry, Shri Prabhu Arts, Science and J M Bohra Commerce Degree College, Shorapur, Yadgiri District. Karnataka-585224, India

^dDepartment of Studies and Research in Environmental Science, UCS, Tumkur University, Tumkur 572 103, Karnataka, India

Abstract. A monoionic bidentate Schiff base ligand of (O, N) type, **LH₂** and their complexes, **1-6** were synthesized from the reaction between homoveratrylamine and β -resorcinaldehyde followed by using respective metal salt. The synthesized **LH₂** and **1-6** have been characterized by spectroscopic and elemental analytical methods. The characterization data revealed that the coordination of **LH₂** to the central metal ion through monoionic bidentate (N,O') type donor. The antimicrobial activity of **LH₂** and **1-6** were evaluated. The metal complexes (**1-6**) were shows comparatively greater antimicrobial activity than ligand (**LH₂**)

Keywords: Schiff base, transition metal, complex, antimicrobial

1 Introduction

Schiff bases containing (O, N) donor atoms can be easily synthesized from simple amines and 2-hydroxyl aldehydes or ketones. Generally, the (O, N) type of ligands are stabilized by characteristic intra-molecular hydrogen bonding between the azomethine nitrogen and phenolic hydrogen and most of them are crystalline solids and have been structurally well characterized. These ligands act as good chelating agents and easily form complexes at room temperature with most of the metal ions in transition elements. This is because the increased nucleophilicity of nitrogen in the azomethine group ($>C=N-$) and phenolate oxygen (PhO^-) to form stable six-membered metal-chelating rings on coordination with metal ions. A number of (O, N) type ligands and their complexes have proven prospective therapeutics and good biological activities viz., antibacterial, antidepressant, antifungal, antiglycation, anti-inflammatory, antimalarial, antioxidant, analgesic, anticonvulsant, antihypertensive

antitumour, antiviral and lipid-lowering[1-10]. The metal complexes of (O, N) type ligands also have shown significant catalytic [11] and biological activities [8-14].

By the consideration of above facts, hereby reported the synthesis of (O,N) type ligand, **LH₂** and their complexes (**1-6**), [M(**LH**)₂], where M=Mn(II), Ni(II), Cu(II), Zn(II) and [M(**LH**)₂Cl], (where M=Fe(III), Co(III)). Further, the antimicrobial activity of all the synthesized **LH₂** and **1-6** was carried out. The structures of the synthesized ligand, **LH₂** and its complexes, **1-6** were given in **Chart 1**.




Chart 1 Structure of **LH₂** and **1-6**

2 Experimental

2.1 Reagents and Materials

2,4-dihydroxybenzaldehyde (β -resorcynaldehyde), 2-(3,4-dimethoxyphenyl)ethan-1-amine, metal salts were purchased from Sigma India Pvt Ltd. The microorganisms viz., *Escherichia coli* (E. coli) [NCIM-5051], *Klebsiella aerogenes* (K. aerogenes) [NCIM-2098], *Pseudomonas desmolyticum* [NCIM-2028] and *Staphylococcus aureus* [NCIM-5022], *Candida albicans* [NCIM-3100] and *Aspergillus flavus* (A. flavus) [NCIM-544] have been purchased from NCL, Pune, India and these strains have been maintained at 4°C. The standard antibiotic and antifungal drugs were received from Hi-Media, Mumbai, India.

2.2 Analytical methods

Melting point of **LH₂** and **1-6** were determined by using melting point and are reported uncorrected. LECO-CHNSO-9320 elemental analyser was used for CHN elemental analysis. The UNI-CAM-UV 2-100 spectrophotometer is used to record UV-visible spectra. FT-IR data were recorded on Agilent spectrophotometer. The Bruker spectrometer (400MHz) with tetramethylsilane (TMS) used as an internal standard to record the ¹³C{¹H} and ¹H NMR spectrum of **LH₂** and **6**.

2.3 Synthesis of ligand (**LH₂**)

The solutions of 2-(2,4-dimethoxyphenyl)ethanamine in absolute ethanol (20 mL) and 2,4-dihydroxybenzaldehyde (1 mmol) in absolute ethanol were mixed along with stirring and is continued for 2h. The solid was separated out. The solvent was removed by using rotary evaporator to gave **LH₂** as yellow solid.

LH₂: Yield: 95%; M.P.:63-65°C; CHN Analysis for C₁₇H₁₉NO₄: Calcd.(Found) %: C 67.76(67.73); H 6.36(6.32); N 4.65(4.67); FT-IR (ATR, ν in cm⁻¹): 3402, 2998, 2935, 1638,

1513, 1465, 1261, 1237, 1024, 845, 797, 603 and 551; UV-vis (λ_{max} in nm): 387, 307, 280 and 259; ^1H NMR (Solvent: $(\text{CH}_3)_2\text{SO}-d_6$, δ in ppm): 13.81 (s, 1H, 2-OH), 9.95 (s, 1H, 4-OH), 8.23 (s, 1H, $>\text{CH}=\text{N}-$), 7.088-7.108 (d, 1H, 6-H), 6.816-6.838 (d, 2H, 14-H, 15-H), 6.712-6.732 (d, 1H, 11-H), 6.202-6.220 (d, 1H, 5-H), 6.123 (s, 1H, 3-H), 3.683 (s, 3H, methoxy), 3.627 (s, 3H, methoxy), 3.501-3.611 (t, 2H, 8-H), 2.750-2.830 (t, 2H, 9-H); $^{13}\text{C}\{^1\text{H}\}$ NMR (Solvent: CDCl_3 , δ ppm): 36.62 (C-9), 55.78 (methoxy), 55.86 (methoxy), 55.93 (C-8), 111.56 (C-5), 112.15 (C-11), 112.54 (C-14), 120.79 (C-15), 120.91 (C-10), 147.77 (C-3), 130.82 (C-1), 134.28 (C-6), 148.94 (C-13), 149.07 (C-12), 163.35 (C-4), 165.18 (C-2), 170.58 (C-7).

2.4 Synthesis of $[\text{M}(\text{LH})_2]$ (1,4-6), where $\text{M}=\text{Mn(II)}$ (1), Ni(II) (4), Cu(II) (5), Zn(II) (6)

A respective metal salt solution (0.29 mmol) in methanol, was added to a stirred solution of LH_2 (0.58 mmol) in methanol followed by triethyl amine (0.58 mmol) at RT for 6-7 h. The consumption of ligand was monitored by Thin Layer Chromatography. The solvent in a reaction mixture was evaporated to dryness using rotavapor to gave respective complex, $[\text{M}(\text{LH})_2]$ (1,4-6).

$[\text{Mn}(\text{LH})_2]$ (1): Brown colour solid. Yield: 80%; M.P.: 246-250°C (decomp.); CHN Analysis for $\text{C}_{34}\text{H}_{36}\text{N}_2\text{MnO}_8$ Calcd.(Found) %: C, 62.29(62.31); H, 5.53(5.55); N, 4.20(4.19); FT-IR (ν in cm^{-1}): 3582, 3517, 2920, 1598, 1514, 1235, 1134, 1024, 844, 763, 639; UV-Vis.: λ_{max} in nm: 282, 305, 347.

$[\text{Ni}(\text{LH})_2]$ (4): Green colour solid; Yield: 80%; M.P.: 247-250°C (decomp.); CHN Analysis for $\text{C}_{34}\text{H}_{36}\text{N}_2\text{NiO}_8$ Calcd.(Found) %: C, 61.93(61.90); H, 5.50(5.49); N, 4.25(4.28); FT-IR (ν in cm^{-1}): 3432, 3064, 3009, 2925, 1622, 1541, 1513, 1417, 1342, 1278, 1235, 1173, 1113, 1022, 845, 823, 797, 629 and 498; UV-Visible (λ_{max} in nm): 253, 270, 330, 404.

$[\text{Cu}(\text{LH})_2]$ (5): Dark violet crystalline solid; Yield: 73%; M.P.: 138-145°C (decomp.); CHN Analysis for $\text{C}_{34}\text{H}_{36}\text{N}_2\text{CuO}_8$ Calcd.(Found) %: C, 61.48(61.45); H, 5.46(5.45); N, 4.22(4.25); FT-IR (ν cm^{-1}): 3433, 3212, 2939, 2675, 1619, 1538, 1451, 1342, 1286, 1259, 1231, 1133, 1023, 845, 761, 740, 707, 679, 615, 520 and 498; UV-Visible (λ_{max} nm): 258, 290, 350.

$[\text{Zn}(\text{LH})_2]$ (6): White solid: Yield: 68%; M.P.: 169-171°C (decomp); CHN Analysis for $\text{C}_{34}\text{H}_{36}\text{N}_2\text{ZnO}_8$ Calcd. (Found) %: C, 61.31(61.30); H, 5.45(5.44); N, 4.21(4.23); UV-Visible (λ_{max} nm): 272, 370; FT-IR: (ν cm^{-1}): 3401, 3010, 2980, 2862, 1586, 1481, 1205, 1099, 843, 744, 639, 482 and 450; ^1H NMR (Solvent: $(\text{CH}_3)_2\text{SO}$, δ ppm): 8.310 (s, 1H, $\text{CH}=\text{N}$), 9.834 (s, 1H, OH), 7.011-7.021 (dd, 1H, H6), 6.876-6.897 (d, 1H, H-3), 6.682- 6.705 (d, 1H, H-5), 6.542-6.590 (dd, 3H, H-11, H-15, H-14), 3.603 (s, 3H, -O-CH₃), 3.474 (s, 3H, -O-CH₃), 3.136-3.291 (t, 2H, -N-CH₂), 2.181-2.292 (t, 2H, -CH₂-Ar). $^{13}\text{C}\{^1\text{H}\}$ NMR (Solvent: CDCl_3 , δ in ppm): 36.60 (C-9), 55.73 (-O-CH₃), 55.87 (-O-CH₃), 62.64 (C8), 111.30 (C5), 112.18 (C11), 114.62 (C14), 117.91 (C10), 123.14 (C15), 130.48 (C1), 135.03 (C6), 135.70 (C3), 147.65 (C13), 148.92 (C12), 164.35 (C4), 170.53 (C2), 171.38 (C7).

2.5 Synthesis of M(III) complexes, $[\text{M}(\text{LH})_2\text{Cl}]$ (2-3), where $\text{M}=\text{Fe(III)}$ (2), Co(III) (3)

A respective metal salt solution (0.165 mmol) prepared in methanol added slowly to a solution of LH_2 (0.33 mmol) in methanol followed by triethyl amine (0.033 mmol) with stirring at RT and continued for 6-7 h. The consumption of ligand was monitored by TLC. The solvent in a reaction mixture was evaporated to dryness using rotavapor to gave respective complex, $[\text{M}(\text{LH})_2\text{Cl}]$ (2-3).

$[\text{Fe}(\text{LH})_2\text{Cl}]$ (2): Dark green colour solid. Yield: 75%; M.P.: 340-345°C(dec.); Element. Anal. Calcd. (Found) $\text{C}_{34}\text{H}_{36}\text{ClN}_2\text{CoO}_8$: C, 58.75(58.71); H, 5.22; N, 4.03(4.04); FT-IR (ν , cm^{-1}): 3627, 3545, 3408, 2142, 1941, 1616, 1514, 1232, 1024, 801, 659; UV-Vis.: λ_{max} in nm: 280, 315.

[Co(LH)₂Cl](3): Dark violet colour solid. Yield: 79%; M.P.:330-332°C(dec.); Element. Anal. Calcd. (Found) C₃₄H₃₆ClN₂FeO₈: C, 59.02(59.04); H, 5.24(5.24); N, 4.05(4.03); FT-IR (ν, cm⁻¹): 3427, 2935, 1578, 1474, 1304, 1232, 1122, 1025, 849, 805, 642; UV-Vis.: λ_{max} in nm: 278, 316.


2.6 Antimicrobial activity

The antimicrobial activity of LH₂ and complexes, 1-6 have been investigated as per the procedure reported [15-17]. The sample solutions of each LH₂ and 1-6 prepared in sterile water by dissolving 0.5mg /50μL and 1mg/100μL for antibacterial activity. A standard solution of Ciprofloxacin was prepared by dissolving 0.005mg/50μL. For antifungal activity, the solutions of LH₂ and complexes (1-6) were made by dissolving 0.25mg/25 μL, 0.5mg/50μL and 0.75mg/75μL. A standard antifungal drug solution of Fluconazole (as a positive control) was made by dissolving 0.2mg/50 μL in sterile water. The region of inhibition of each sample was measured after 72 hours of the incubation period. For each compounds, duplicates were maintained and antimicrobial activity results were reported.

3. Results and Discussion

3.1 Synthesis

The (O, N) type ligand LH₂ was synthesized by the reaction of 2,4-dihydroxy benzaldehyde and 2-(3,4-dimethoxyphenyl)ethan-1-amine [16,17]. The metal complexes, [M(LH)₂] (1-6), where M=Mn(II), Ni(II), Cu(II), Zn(II) and [M(LH)₂Cl], (where M=Fe(III), Co(III)) were synthesized by the reaction of LH₂ with respective metal salts in 2:1 ratio as given in Scheme 1.



Scheme 1 Synthesis of **LH₂** and **1-6**

LH₂ was freely dissolved in CHCl_3 , CH_2Cl_2 , CH_3OH , $\text{C}_2\text{H}_5\text{OH}$, DMF, DMSO, and insoluble in benzene, toluene and n-hexane. All the complexes, **1-6** were dissolved in CHCl_3 , CH_2Cl_2 , DMSO and DMF.

UV-visible spectroscopy

The UV-visible data of **LH₂** and **1-6** were taken down by using DMSO and reported in **Fig. 1**. Within the UV-visible spectrum of **LH₂**, three strongly intense absorption bands watched at λ_{max} , 280, 307 and 387 nm. The primary two absorption bands obtained at λ_{max} , 280 and 307 nm were due to the $\pi \rightarrow \pi^*$ transitions of the aromatic ring. The band showed at λ_{max} , 387 nm because of the transitions within the ligand charge transfer (ILCT) inside the delocalized π framework. Within the UV-visible spectra of **1-6** the groups watched between λ_{max} , 250-260 nm show $\pi \rightarrow \pi^*$ transition with two shoulders in interims of λ_{max} , 270-274 nm and 278-282 nm which indicate to another $\pi \rightarrow \pi^*$ and $n \rightarrow \pi^*$ excitations. In all the complexes these bands found blue shift of about 10-15 nm relative to **LH₂**. The bear of band watched around λ_{max} , ~390 to 400 nm in all complexes because of charge transfer transition between **LH₂** and central metal ion in complexes (LMCT) [16,17].




Fig.1 UV-Visible spectra of **LH₂** and **1-6**

IR spectroscopy

The band at ν , 3402 cm^{-1} appeared due to O-H stretching for **LH₂**. The $>\text{C}=\text{N}$ stretching frequency appeared at 1638 cm^{-1} and was resulted red shift of about $20\text{-}50\text{ cm}^{-1}$ in **1-6** complexes, indicated a strong coordination between imine nitrogen and the central metal ion. Owing to the chelation ligand through the phenoxide (O^-) gather and the band moved to higher wave numbers in **1-6**. The bands between ν , 1578 and 1500 cm^{-1} in **LH₂** and **1-6** appeared due to $>\text{C}=\text{C}<$ vibration in ary ring [17]. The IR spectra of **LH₂** and **1-6** complexes are as in **Fig.2** to **8**.




Fig.2 FT-IR spectrum of LH₂




Fig.3 FT-IR spectrum of [Mn(LH)₂](1)




Fig.4 FT-IR spectrum of [Fe(LH)₂Cl](2)




Fig.5 FT-IR spectrum of [Co(LH)₂Cl](3)




Fig.6 FT-IR spectrum of [Ni(LH)₂](4)




Fig.7 FT-IR spectrum of [Cu(LH)₂](5)




Fig.8 FT-IR spectrum of [Zn(LH)₂](6)

¹H NMR spectroscopy

The ¹H NMR spectrum of **LH₂** and complex, **6** were shown in Fig. 9 to 10. In **LH₂**, the Ar-CH₂- and -CH₂-N protons appeared at δ, 2.750-2.830 and 3.501-3.611 ppm respectively as triplets. The two -OCH₃ groups gave two independent singlets at δ, 3.68 and 3.62 ppm. The -OH proton *ortho* to C=N group appeared as singlet in **LH₂** at δ, 13.81 ppm, and found highly deshielded due to intra-molecular H-bonding between O-H...N where as the signal for OH proton *para* to C=N group was appeared at δ, 9.95 ppm as singlet. The proton of CH=N in **LH₂** was observed at δ, 8.23 ppm as a singlet.

In complex **6**, the CH=N proton showed a downfield shift of 0.09 ppm when compared to that of the ligand **LH₂**. The absence of -OH proton signal in the proton NMR spectrum of zinc complex **6** indicate the coordination of (**LH₂**) to the metal through the *ortho*-PhO⁻. In complex **6** the NCH₂ (0.4 ppm) and CH₂Ar (0.6 ppm) protons have been found to be shielded than ones protons in ligand **LH₂**[16,17].




Fig.9 ¹H NMR spectrum of ligand (**LH₂**)




Fig.10 ¹H NMR spectrum of **[Zn(LH₂)₂](6)**

¹³C NMR spectroscopy

In the ¹³C-NMR spectrum of **LH₂** (Fig.11), the azomethine (>C=N-), C2 (*ortho* to PhC-O) and C4 (*meta* to PhCO⁻) carbon signals appeared at δ, 170.58, 165.18 and 163.35 ppm respectively. The peaks for OCH₃ carbons appeared at δ, 55.7 and 55.8 ppm.

In the ^{13}C -NMR spectrum of complex **6** (Fig.12), the peaks for azomethine ($>\text{C}=\text{N}-$), C2 (*ortho* to $\text{PhC}-\text{O}$), and C4 (*meta* to PhCO^-) carbons found deshielded by about 2-6 ppm relative to the respective carbon signals in LH_2 .

The NMR spectra of LH_2 and **6** revealed that the LH_2 coordinated to $\text{Zn}(\text{II})$ ion as monoanionic bidentate (N,O^-) type[16,17].




Fig.11 $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of LH_2 .




Fig.12 $^{13}\text{C}\{^1\text{H}\}$ NMR spectrum of $[\text{Zn}(\text{LH}_2)_2](\mathbf{6})$

Antimicrobial activity studies of LH_2 and 1-6 complexes

The antimicrobial properties of LH_2 type (O,N) and metal complexes (**1-6**) as given within the Fig.13 and 14. The exploratory points of interest and region of restraint comes about in regard of both antimicrobial movement of LH_2 and **1-6** completely different concentrations against the microbial strains as given in Table 1 and Table 2 individually. The results revealed that all the complexes were way better antimicrobial specialists than the ligand. The antimicrobial action increments with expanding concentration. Among the complexes tried copper and zinc complex appeared superior antimicrobial action[16,17].




Fig.13 Antibacterial activity of LH₂ and 1-6

Table 1 Antibacterial activity of new compounds LH₂ and 1-6 and a standard Ciprofloxacin

| Compound | Treatment | <i>E. coli</i> (Mean ± SE) | <i>K.aerogenes</i> (Mean ± SE) | <i>S. aureus</i> (Mean ± SE) | <i>P. desmolyticum</i> (Mean ± SE) |
|-----------------------------|----------------|-------------------------------|-----------------------------------|---------------------------------|---------------------------------------|
| Ciprofloxacin | 0.005 mg/50 µl | 13.67 ± 0.03 | 12.33 ± 0.03 | 14.00 ± 0.00 | 15.60 ± 0.03 |
| LH ₂ | 0.5 mg/50 µl | 2.07 ± 0.07 | 1.10 ± 0.06 | 1.00 ± 0.00 | 1.00 ± 0.00 |
| | 1 mg/100 µl | 3.23 ± 0.07 | 3.43 ± 0.12 | 2.50 ± 0.07 | 2.60 ± 0.06 |
| [Mn(LH) ₂](1) | 0.5 mg/50 µl | 1.30 ± 0.06 | 0.50 ± 0.00 | 1.10 ± 0.06 | 2.00 ± 0.00 |
| | 1 mg/100 µl | 2.53 ± 0.03 | 1.17 ± 0.17 | 3.43 ± 0.12 | 4.00 ± 0.00 |
| [Fe(LH) ₂ Cl](2) | 0.5 mg/50 µl | 1.10 ± 0.06 | 1.00 ± 0.00 | 2.07 ± 0.07 | 1.00 ± 0.00 |
| | 1 mg/100 µl | 2.00 ± 0.00 | 2.50 ± 0.07 | 3.23 ± 0.07 | 2.53 ± 0.03 |
| [Co(LH) ₂ Cl](3) | 0.5 mg/50 µl | 1.00 ± 0.00 | 2.00 ± 0.00 | 1.00 ± 0.00 | 4.67 ± 0.17 |
| | 1 mg/100 µl | 1.67 ± 0.17 | 3.43 ± 0.23 | 2.50 ± 0.07 | 6.67 ± 0.17 |
| [Ni(LH) ₂](4) | 0.5 mg/50 µl | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 |
| | 1 mg/100 µl | 2.60 ± 0.06 | 2.37 ± 0.09 | 3.00 ± 0.00 | 3.67 ± 0.17 |
| [Cu(LH) ₂](5) | 0.5 mg/50 µl | 0.50 ± 0.00 | 1.00 ± 0.00 | 1.00 ± 0.00 | 2.00 ± 0.00 |
| | 1 mg/100 µl | 1.67 ± 0.17 | 2.00 ± 0.00 | 2.67 ± 0.17 | 3.23 ± 0.07 |
| [Zn(LH) ₂](6) | 0.5 mg/50 µl | 1.15 ± 0.02 | 1.10 ± 0.02 | 1.95 ± 0.00 | 2.20 ± 0.02 |
| | 1 mg/100 µl | 2.95 ± 0.01 | 2.01 ± 0.01 | 3.05 ± 0.01 | 3.32 ± 0.00 |

Mean ± SE of zone of inhibition in mm




Fig.14 Antifungal activity of LH₂ and 1-6

Table 2 Antifungal activity of standard Fluconazole and new compounds LH₂ and 1-6.

| Compound | Treatment | C. albicans (Mean ± SE) | A. flavus (Mean ± SE) |
|------------------------------|----------------|----------------------------|--------------------------|
| Fluconazole | 0.2 mg/50µl | 11.50 ± 0.06 | 10.27 ± 0.03 |
| LH ₂ | 0.25 mg /25 µl | 1.57 ± 0.03 | 1.00 ± 0.00 |
| | 0.5 mg /50 µl | 3.67 ± 0.03 | 2.33 ± 0.33 |
| [Mn(LH) ₂](1) | 0.25 mg /25 µl | 1.57 ± 0.03 | 1.00 ± 0.00 |
| | 0.5 mg /50 µl | 3.67 ± 0.03 | 2.50 ± 0.06 |
| [Fe(LH) ₂ Cl] (2) | 0.25 mg /25 µl | 1.00 ± 0.00 | 1.50 ± 0.06 |
| | 0.5 mg /50 µl | 2.33 ± 0.33 | 2.00 ± 0.00 |
| [Co(LH) ₂ Cl] (3) | 0.25 mg /25 µl | 1.00 ± 0.00 | 1.37 ± 0.03 |
| | 0.5 mg /50 µl | 1.20 ± 0.00 | 2.17 ± 0.03 |
| [Ni(LH) ₂](4) | 0.25 mg /25 µl | 1.50 ± 0.06 | 1.00 ± 0.00 |
| | 0.5 mg /50 µl | 2.33 ± 0.03 | 1.67 ± 0.03 |
| [Cu(LH) ₂](5) | 0.25 mg /25 µl | 1.60 ± 0.03 | 0.55 ± 0.00 |
| | 0.5 mg /50 µl | 2.33 ± 0.03 | 2.27 ± 0.03 |
| [Zn(LH) ₂](6) | 0.25 mg /25 µl | 1.82 ± 0.01 | 1.60 ± 0.00 |
| | 0.5 mg /50 µl | 3.01 ± 0.02 | 2.41 ± 0.02 |

Mean ± SE of zone of inhibition in mm

4. Conclusions

A new ligand of Schiff's base LH₂ has been synthesized by 2-(3,4-dimethoxyphenyl) ethan-1-amine condensed with 2,4-dihydroxy benzaldehyde and their metal complexes, 1-6 were synthesized. The LH₂ and 1-6 were well known from CHN analysis and spectroscopic investigation. The antimicrobial and antibacterial activities of LH₂ and 1-6 were assessed and

results were noteworthy exercises. The microbial development restraint act of ligand has been expanded on complexation.

Acknowledgements.

P Raghavendra Kumar acknowledges the financial assistance for the project No. 01(2701)/12/EMR-II provided by CSIR, New Delhi, India.

References

- [1] Afanas' ev, I. B., Derozhko, A. I., Brodskii, A. V., Kostyuk, V. A., & Potapovitch, A. I.: Chelating and free radical scavenging mechanisms of inhibitory action of rutin and quercetin in lipid peroxidation. *Biochemical pharmacology*, 38(11), pp.1763-1769(1989)
- [2] Asiri, A. M., & Khan, S. A.: Synthesis and anti-bacterial activities of some novel schiff bases derived from aminophenazone. *molecules*, 15(10), pp.6850-6858(2010)
- [3] Borisova, N. E., Reshetova, M. D., & Ustynyuk, Y. A.: Metal-free methods in the synthesis of macrocyclic Schiff bases. *Chemical reviews*, 107(1), pp.46-79(2007)
- [4] Reddy, P. M., Sarangapani, M., Hanmanthu, G., Geeta, B., Rani, K. S., & Ravinder, V.: Synthesis of N4 donor macrocyclic Schiff base ligands and their Ru (II), Pd (II), Pt (II) metal complexes for biological studies and catalytic oxidation of didanosine in pharmaceuticals. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, 97, pp.189-196(2012)
- [5] Sinha, D., Tiwari, A. K., Singh, S., Shukla, G., Mishra, P., Chandra, H., & Mishra, A. K.: Synthesis, characterization and biological activity of Schiff base analogues of indole-3-carboxaldehyde. *European journal of medicinal chemistry*, 43(1), pp.160-165(2008)
- [6] Pandeya, S. N., Sriram, D., Nath, G., & De Clercq, E.: Synthesis, antibacterial, antifungal and anti-HIV evaluation of Schiff and Mannich bases of isatin and its derivatives with triazole. *Arzneimittelforschung*, 50(01), pp.55-59(2000)
- [7] Alam, M. S., Choi, J. H., & Lee, D. U.: Synthesis of novel Schiff base analogues of 4-amino-1, 5-dimethyl-2-phenylpyrazol-3-one and their evaluation for antioxidant and anti-inflammatory activity. *Bioorganic & medicinal chemistry*, 20(13), pp.4103-4108(2012)
- [8] Tümer, M., Köksal, H., Serin, S., & Digrak, M.: Antimicrobial activity studies of mononuclear and binuclear mixed-ligand copper (II) complexes derived from Schiff base ligands and 1, 10-phenanthroline. *Transition Metal Chemistry*, 24(1), pp.13-17(1999)
- [9] (a) N. Bharti, M.R. Maurya, F. Naqvi, A. Azam, *Bioorg. Med. Chem.* 10 (2010) 2243–2245
Bharti, N., Maurya, M. R., Naqvi, F., & Azam, A.: Synthesis and antiamoebic activity of new cyclooctadiene ruthenium (II) complexes with 2-acetylpyridine and benzimidazole derivatives. *Bioorganic & medicinal chemistry letters*, 10(20), pp.2243-2245(2000)
- [10] Chu, Z., & Huang, W.: Syntheses and structures of two new bis-N, O-bidentate Schiff base ligands and their respective copper (II) complexes with dinuclear double-helical configuration. *Journal of molecular structure*, 837(1-3), pp.15-22(2007)
- [11] Gupta, K. C., & Sutar, A. K.: Catalytic activities of Schiff base transition metal complexes. *Coordination Chemistry Reviews*, 252(12-14), pp.1420-1450(2008)(b) Vigato, P. A., & Tamburini, S.: The challenge of cyclic and acyclic Schiff bases and related derivatives. *Coordination Chemistry Reviews*, 248(17-20), pp.1717-2128(2004)

- [12] Harinath, Y., Reddy, D. H. K., Kumar, B. N., Apparao, C., & Sessaiah, K.: Synthesis, spectral characterization and antioxidant activity studies of a bidentate Schiff base, 5-methyl thiophene-2-carboxaldehyde-carbohydrazone and its Cd (II), Cu (II), Ni (II) and Zn (II) complexes. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*, 101, pp.264-272(2013)
- [13] Satheesh, C. E., Sathish Kumar, P. N., Kumara, P. R., Karvembu, R., Hosamani, A., & Nethaji, M.: Half-sandwich Ru (II) complexes containing (N, O) Schiff base ligands: Catalysts for base-free transfer hydrogenation of ketones. *Applied Organometallic Chemistry*, pp.33(10), e5111(2019)
- [14] Ramesh, M., Kumar, M. D., Jaccob, M., Kaleeswaran, D., & Venkatachalam, G.: Ru (III) mediated CH bond activation of N-(naphthyl) salicylaldehyde and related Schiff base ligands: Synthesis, structure, DFT study and catalytic activity. *Inorganic Chemistry Communications*, 85, pp.26-31(2017)
- [15] (a) Sztanke, K., Maziarka, A., Osinka, A., & Sztanke, M.: An insight into synthetic Schiff bases revealing antiproliferative activities in vitro. *Bioorganic & Medicinal Chemistry*, 21(13), pp.3648-3666(2013)
- [16] Satheesh, C. E., Kumar, P. R., Sharma, P., Lingaraju, K., Palakshamurthy, B. S., & Naika, H. R.: Synthesis, characterisation and antimicrobial activity of new palladium and nickel complexes containing Schiff bases. *Inorganica Chimica Acta*, 442, pp.1-9(2016)
- [17] Satheesh, C. E., Kumar, P. R., Shivakumar, N., Lingaraju, K., Krishna, P. M., Rajanaika, H., & Hosamani, A.: Synthesis, structural characterization, antimicrobial and DNA binding studies of homoleptic zinc and copper complexes of NO Schiff bases derived from homoveratrylamine. *Inorganica Chimica Acta*, 495, 118929(2019)